First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
Standard
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. / Untch, Michael; Muscholl, Michael; Tjulandin, Sergei; Jonat, Walter; Meerpohl, Hans-Gerd; Lichinitser, Mikhail; Manikhas, Alexey G; Coumbos, Alexandra; Kreienberg, Rolf; Andreas, Du Bois; Harbeck, Nadia; Jackisch, Christian; Müller, Volkmar; Pauschinger, Matthias; Thomssen, Christoph; Lehle, Michaela; Catalani, Olivier; Lück, Hans-Joachim.
In: J CLIN ONCOL, Vol. 28, No. 9, 9, 2010, p. 1473-1480.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
AU - Untch, Michael
AU - Muscholl, Michael
AU - Tjulandin, Sergei
AU - Jonat, Walter
AU - Meerpohl, Hans-Gerd
AU - Lichinitser, Mikhail
AU - Manikhas, Alexey G
AU - Coumbos, Alexandra
AU - Kreienberg, Rolf
AU - Andreas, Du Bois
AU - Harbeck, Nadia
AU - Jackisch, Christian
AU - Müller, Volkmar
AU - Pauschinger, Matthias
AU - Thomssen, Christoph
AU - Lehle, Michaela
AU - Catalani, Olivier
AU - Lück, Hans-Joachim
PY - 2010
Y1 - 2010
N2 - A high incidence of congestive heart failure (CHF) has been observed in patients with metastatic breast cancer (MBC) receiving doxorubicin-based chemotherapy and trastuzumab. The Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial evaluated trastuzumab plus cyclophosphamide and the less cardiotoxic anthracycline epirubicin.
AB - A high incidence of congestive heart failure (CHF) has been observed in patients with metastatic breast cancer (MBC) receiving doxorubicin-based chemotherapy and trastuzumab. The Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial evaluated trastuzumab plus cyclophosphamide and the less cardiotoxic anthracycline epirubicin.
M3 - SCORING: Zeitschriftenaufsatz
VL - 28
SP - 1473
EP - 1480
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 9
M1 - 9
ER -